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INTRODUCTION 
Spinal Cord Injury 
The field of stem cell research has created an opportunity to use cell replacement 
therapies for a number of diseases and injuries. One example is spinal cord injury. Spinal cord 
injury is a prevalent medical issue that has few treatment options. The Centers for Disease 
Control and Prevention predict that about 200,000 people in the United States are living with 
spinal cord injury (SCI). Annually, 12,000-20,000 people become new patients. Most of these 
cases occur in young adults (18-35 years of age) who are mostly male. Of all SCIs, 46% are due 
to motor vehicle accidents. Other causes of SCI include acts of violence (i.e. gunshot wounds), 
sports injuries, and falls. SCI results in neurologic impairments in the central nervous system 
which includes paraplegia, tetraplegia, and respiratory, urinary, and gastrointestinal problems. 
Psychological side effects also occur including lifetime recurrence of depression and anxiety. For 
patients of SCI, the average medical cost annually is $15,000-$30,000 
[49]
. 
Two types of SCI exist based on the severity of the injury. The severity is determined 
clinically by “completeness” based on neurological examination [43]. According to the Sacral 
Sparring definition, patients with a complete SCI have a total loss of motor and sensory function 
below the site of injury, or in the sacral segments 
[43]
. Incomplete SCI includes some ability to 
convey messages to the brain as they retain minimal motor and sensory function below the site of 
injury in the sacral segments 
[43]
. Both types are life-altering and lead to a life of treatment and 
rehabilitation. 
 In cases of spinal cord injury, there are two stages: the initial injury (e.g. crushed 
vertebrae from a car accident), and a secondary injury which involves an excessive release of 
neurotransmitters and cytokines to the injury site. During secondary injury other mechanisms 
occur that worsen the functional impairment of the spinal cord including shifts in electrolytes, 
lipid peroxidation, accumulation of excitatory amino acids, and an overabundance of free radicals 
[54]
. There are a number of vascular changes that occur including loss of auto regulation, 
neurogenic shock, hemorrhage, and reduction of blood flow. Electrolyte changes occur including 
increased intracellular calcium, extracellular potassium, and sodium permeability. Other changes 
are biochemical, like increases in neurotransmitter accumulation, free-radical production, and 
lipid peroxidation that lead to neuronal death 
[46]
.  
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Oligodendrocytes  
 Oligodendrocytes are a glial cell lineage in the central nervous system that generate 
myelin membranes rich in lipids. Oligodendrocytes arise from oligodendrocyte progenitor cells 
(OPCs). PDGFR alpha positive cells are believed to be the source of OPCs in the spinal cord. 
Previous experiments have shown that PDGFR alpha positive cells in the optic nerve and spinal 
cord co-label with OPC markers such as NG2 or Olig1/2. PDGFR alpha positive cells all 
differentiated into oligodendrocytes when cultured in defined medium 
[13]
. During mid-
neurogenesis OPCs arise from neuroepithelial precursor cells 
[50]
. This occurs in mice around E15 
and mature into adult oligodendrocytes by E20/P1 
[52]
 (Figure1). OPCs disperse from the ventral 
to the dorsal section of the spinal cord around E12.5 in the mouse in response to sonic hedgehog 
signaling from the notochord and the floor plate and are dispersed throughout the cord around 
E14.5 (Figure 2) 
[41]
 
[36][38]
. Once cells reach the white matter, they become multi-processed and 
may differentiate into immature oligodendrocytes 
[29]
.  After the initial migration, dorsal OPCs 
arise independent of sonic hedgehog signaling 
[36]
. OPCSs are able to migrate several millimeters 
during development into the parenchyma where they differentiate into mature oligodendrocytes 
that can myelinate numerous axons 
[36]
.  
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Figure 1. Oligodendrocyte Differentiation with markers for each stage. 
Oligodendrocytes arise from neural stem cells in the ventral part of the floor plate 
and mature into oligodendrocytes after migration into white matter 
[52]
. 
 
 
Figure 2. Oligodendrocyte progenitor cells in the mouse spinal cord. 
PDGFRα+ oligodendrocyte progenitor cells appear in the ventral VZ on E13 
(arrow), then they proliferate and migrate away from the midline. Within a day-
and-a-half (E14.5) they spread through most of the cord 
[39]
. 
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Oligodendrocytes role in spinal cord injury 
 Neurons and oligodendrocytes are susceptible to the secondary injury of SCI. Previous 
studies in rats and monkeys have shown a pattern of expression of apoptosis after SCI shows 
secondary cellular degeneration of oligodendrocytes within the fiber tracts in response to the 
degeneration of damaged axons at the injury site 
[5]
. During secondary injury, most 
oligodendrocytes are lost from the epicenter of the injury to surrounding tissue, due to apoptosis 
and necrosis 
[22]
. Loss of oligodendrocytes is important because they function as myelin-forming 
cells that provide a myelin sheath for axonal conductivity. With damaged axonal conductivity, 
propagation of axon potentials is blocked and the recovery of neural function following SCI is 
limited 
[54]
. After injury, endogenous oligodendrocyte progenitor cells migrate under the control 
of Sonic Hedgehog protein and BMP4 
[28]
. Oligodendrocyte progenitor cells respond to injury 
with proliferation, migration, and eventual differentiation into myelinating mature 
oligodendrocytes 
[8]
. Unfortunately, the spontaneous remyelination that occurs after migration is 
not sufficient for effective repair 
[1]
.  
Current treatments for SCI include surgery to relieve compression and remove debris, 
medications for pain control, and long-term rehabilitation to strengthen muscle. There is no 
current treatment that addresses the issue of demyelination, one reason for loss of neurological 
function. Some neural function after SCI only requires about 5-10% myelinated axons at the 
lesion site 
[54]
. Therefore, experimental procedures that may increase myelination, providing some 
improved neurological function, are at a high demand. Cell therapy in combination with 
immediate injury treatment may be the most beneficial therapy for spinal cord injury by reducing 
further damage and replacing important cell types in the spinal cord.  
 
Experimental Treatment of Spinal Cord Injury 
 There are two main experimental options to overcome the problem of demylinated axons. 
The first involves preventing axonal demyelination with the addition of neurotrophic factors such 
as BDNF or LIF. Koda et al. (2002) suggest that BDNF suppresses delayed apoptosis of 
oligodendrocytes after SCI if injected immediately or three days after injury, as seen in a reduced 
number of TUNEL-positive cells in a rat model 
[21]
. Previous studies have shown that LIF can 
support oligodendrocyte survival by promoting differentiation and survival of oligodendrocyte 
progenitor cells. In rat models LIF-mediated reduction of oligodendrocyte apoptosis decreased 
the amount of axonal demyelination 
[7]
. Another study in 2004 showed that injection of 
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minocycline, a form of tetracycline, reduced the numbers of apoptotic oligodendrocytes in nerve 
fiber tracts near the site of injury, suggesting minocycline has a neuroprotective effect 
[44]
. 
Unfortunately, if not treated immediately after spinal cord injury, prevention of axonal 
demyelination is not sufficient to have a significant effect. 
 The second experimental approach involves enhancing axonal remyelination through cell 
transplantation. Originally, Schwann cells seemed to be a potential source for therapy because 
they can be autologous to the patient and showed improvement in thoracic SCI models. Schwann 
cells are myelin-forming cells in the peripheral nervous system and participate in remyelination; 
however, they do not have efficient integration into the central nervous system due to astrocyte 
inhibition 
[12]
.  Schwann cells may also differentiate into two other cell types that are non-
myelinating 
[18]
. 
Another source of transplantable cells is neural precursors which are multipotent stem 
cells that may differentiate into the three neural cell types: neurons, astrocytes, and 
oligodendrocytes. Work by Mothe and fellow researchers found that neural stem/progenitor cells 
that were transplanted as neurospheres, produced cells that primarily expressed an 
oligodendrocytic phenotype. 73% of grafted cells differentiated into oligodendrocytes when 
transplanted into the white matter 
[31]
. Bambakidis and Miller (2004) transplanted oligodendrocyte 
precursor cells into lesion sites of rats with SCI. The rats had significant locomotor improvement 
and the electrophysiological results were comparable to positive control animals up to 28 days 
post-transplantation. The cells survived, integrated, and proliferated 
[3]
. 
 
Oligodendrocyte progenitor cells from multiple sources 
 To generate high numbers of OPCs, techniques using embryonic stem cells as well as 
induced pluripotent stem cells were studied. In 2005, Keirstead and colleagues showed that 
hESC-derived oligodendrocyte progenitor cells could remyelinate axons and promote 
improvement of motor function in adult rats with SCI when they were transplanted 7 days post 
injury. Transplanted cells that were injected 10 months after injury were still able to survive and 
distribute around the site of injury, however there was no locomotor improvement 
[16]
. From this 
study, the authors proposed that there is a window of opportunity in treatment.  
Initial iPSC studies looked at the potential of iPS-derived oligodendrocytes from mouse 
cells. A group in 2011 generated mature oligodendrocytes that myelinated axons in vitro and in 
vivo, when transplanted into the corpus callosum of a mouse model of demyelination 
[6]
. Also in 
2011, a group was able to establish oligodendrocyte progenitor cells from human induced 
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pluripotent stem cells that came from adult somatic cell lines 
[33]
. However, the differentiation 
efficiency was low (less than 0.01%) 
[33]
. Another experiment in 2013, also used human IPS cell 
lines to obtain OPCs identified with Olig2, PDGFRα, NKX2.2, and Sox10. The OPCs were 
neonatally engrafted and myelinated shiverer mice brains which increased survival compared 
with untreated controls 
[51]
. Although these are significant findings and hold great potential for 
therapies, there are a few problems with using hESC or IPSC-derived OPCs. Firstly, there are the 
ethical concerns surrounding the use of embryonic stem cells. Secondly, both hESC and IPSC 
have a potential to cause teratomas due to some cells undifferentiating from a pluripotent state. 
Finally, hESCs are not autologous to the patient. Cell transplantation of allogenic cells may 
require immune suppression in the patient, causing a number of other complications and 
unwanted side effects. IPSC methods may take around 10 months to establish autologous OPCs 
from patient somatic cells; therefore, this strategy would require further refinement.  
 
Direct Reprogramming 
An alternative and upcoming strategy to using iPSCs or ESCs is direct reprogramming. 
Direct reprogramming is defined as the generation of a desired cell type by over expression of 
lineage-specific transcription factors 
[14]
. Often, the reprogramming involves crossing of the germ 
layers; for example, reprogramming fibroblasts to neurons 
[10]
. One of the benefits of using direct 
reprogramming is that it may take less time than IPSC because it skips the stage needed to return 
cells to an undifferentiated state (Figure 3). Direct reprogramming can be dated back to the 
1960’s when John Gurdon reprogrammed a nucleus of a differentiated frog cell to a totipotent 
state when the nucleus was transferred into an enucleated egg. In the 1980’s the Weintraub team 
reprogrammed fibroblasts into skeletal muscle cells using MyoD. Another experiment by Zhou 
included reprogramming pancreatic exocrine cells to beta cells with three transcription factors: 
Ngn3, Pdx1, and Mofa. These experiments represent the two types of direct reprogramming: 
somatic cell-specific factor mediated direct reprogramming, which targets a specific somatic cell 
using somatic-cell specific transcription factors or pluripotent cell-specific factor mediated, which 
uses the induced pluripotent stem cell factors introduced by Yamanaka 
[19]
. 
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Figure 3. Generation of cell types by two techniques. Desired cell types may be 
obtained by either direct reprogramming or reprogramming with the iPSC stage. 
[14] 
 
Somatic cell-specific transcription factor mediated direct reprogramming has been used 
to develop a variety of cell types (Figure 4). This includes neural stem cells (NSCs) or neural 
progenitor cells. The Han group reprogrammed mouse fibroblasts to induced neural stem cells 
using a host of factors including Brn4, Pou3f4, Sox2, Klf4, and C-Myc. Thier also induced neural 
stem cells with three or four factors that included Sox2, Klf4, C-Myc, and with or without Oct4 
[48]. Ring’s group established NSCs that were self-renewable, multipotent, and could be 
differentiated into a neural lineage with just one factor, Sox2 
[40]
.  Treatments for spinal cord 
injury would benefit most from a more lineage-specific progenitor cell due to the goal being to 
replace mostly oligodendrocytes. Therefore, the ultimate experiment would produce 
oligodendrocyte precursor cells that could survive after transplantation, and myelinate axons in 
the injured area. In 2011, Marius Wernig’s group was able to convert mouse fibroblasts to self-
renewing tripotent neural precursor cells using three factors out of an original 11 candidate genes. 
After adding and deleting factors, Wernig suggested that FoxG1, Brn2, and Sox2 were able to 
induce neural precursor cells that differentiate into neurons and glial cells 
[25]
. FoxG1 and Sox2 
were able to produce neurons and some glial cells. With the addition of Brn2, the neurons were 
immature and astrocytes and oligodendrocyte populations increased 
[25]
. Therefore, Wernig 
suggested that FoxG1 and Brn2 alone can induce a more pure oligodendrocyte population. 
Wernig’s group followed up this experiment in 2013, where a set of three factors (Sox10, Olig2, 
and Zfp536) reprogrammed mouse and rat fibroblasts to what they termed induced 
oligodendrocyte progenitor cells that gave rise to mature oligodendrocytes 
[56]
. Another group 
  8 
repeated this work using mouse fibroblasts and another set of three different transcription factors: 
Nkx6.2, Sox10, and Olig2 
[32]
.  
 
 
Figure 4. Direct reprogramming of various cell types. Pluripotent and somatic cell 
specific direct reprogramming can be used to create a variety of cell types across different 
lineages 
[4]
. 
 
Olig2Cre-ER System 
 As previously mentioned, there are a variety of transcription factors that are used to 
designate stages of oligodendrocyte development. These include Olig1, Olig2, and Sox10 
[18]
. 
Olig2 is a basic helix-loop-helix factor that is induced by sonic hedgehog in the ventral neural 
tube and is important for motor neuron and oligodendrocyte development 
[45]
. Olig2 starts 
expressing in the pMN domain of the mouse spinal cord around E8.5 and is expressed in 
adulthood by oligodendrytic cells. Early Olig2+ cells generate motor neurons, but after E12.5, 
they only produce glial cells 
[26]
. Therefore, Olig2 is used as a cell marker for identification of 
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oligodendrocyte lineage cells. Figure 4 shows Olig2 expression in the mouse spinal cord 
[23]
. In 
2002, the Olig2 Cre-ER mouse strain was created. Exon 2 of the Olig2 locus was replaced with a 
tamoxifen-inducible Cre recombinase (Cre-ER
TM
) (Figure 5). Mutant mice were backcrossed with 
C57BL/6N mice. We decided to use this system because it provides live fluorescence imaging. 
When tamoxifen is added and once there is expression of Olig2, the Cre is activated, enters the 
nucleus, and recombines the targeted vector to express the reporter gene. Reporter gene 
expression stays on for the duration of the experiment making any positive cells identifiable even 
if the Olig2 expression in the cell declines or fades.  
 
 
 
 
 
 
 
Figure 5. Olig2 expression in mouse spinal cord. E16.5 mouse spinal cords show expression of 
Olig2 
[23]
. 
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Figure 6. The targeted mutation of the Olig2 locus to create Olig2Cre-ER mice. Exon 2 of 
the Olig2 Locus was targeted for a mutation to replace with Cre-ER
TM
. 
[45] 
 
With previous experimentation considered, the goal of this project was to use the tool of 
direct reprogramming to efficiently reprogram mouse embryonic fibroblasts using a simple 
retroviral method into oligodendrocyte progenitor cells using the two factors Wernig’s group 
proposed would result in a more pure population of OPCs: FoxG1 and Brn2. We also attempted 
to expand the Sox2 protocol first reported by Ring’s group by differentiating the neural precursor 
cells to an oligodendrocyte progenitor lineage. We hypothesize that oligodendrocyte progenitor 
cells resulting from direct reprogramming would be consistent with the hallmarks of 
oligodendrocyte progenitor cells (i.e. express OPC-specific genes) and would be able to express 
myelin basic protein (MBP) in vitro. The goal is to have a stable population of oligodendrocyte 
progenitor cells that will engraft, survive, and myelinate axons in an in vivo mouse or rat model.
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Methods 
 
 Mouse embryonic fibroblasts taken from an Olig2Cre-ER knock-in mouse were used for 
a direct reprogramming protocol used to produce oligodendrocyte progenitor cells. Different 
methods of virus production were tested to find the most efficient method. Protocols for 
reprogramming were taken from previous publications with minor alterations 
[25][40]
.Transfection 
efficiency was assessed along with morphological changes and positive fluorescence of OPC 
markers for positive identification of any OPCs produced.  
 
Genotyping 
 First, to establish a colony of transgenic mice that could express Cre upon tamoxifen 
addition, Olig2Cre-ER knock-in mice from a strain created by Dr. Takebayashi were ordered 
from Riken. An Olig2Cre-ER female mouse was mated with a BL6 male to establish a colony. 
Genotyping was performed to verify transgene expression. Tail tips were taken from all offspring. 
DNA extraction was performed using the Promega Wizard
®
 Genomic DNA Purification Kit 
protocol. Riken genotyping PCR protocol (Table 1) was used for each DNA sample with three 
primers: Common sense, Olig2KlCre-Er, and Olig2 (Table 2). Gel electrophoresis was performed 
to assess a positive or negative expression (Figure 6). All transgene negative offspring were 
sacrificed while positive mice were kept for breeding with a reporter mouse for fibroblast 
extraction. 
 
Step Temp   C) Time (sec) Notes 
1 95 900  
2 94 30  
3 60 90  
4 72 90 30 Cycle Repeat 
5 72 600  
Table 1. PCR protocol for genotyping of Olig2Cre-ER mice. The PCR protocol was slightly 
altered changing the temperature of 63 to 60 due to initial inefficient results.  
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Primer Sequence Concentration 
Common Sense TCGAGAGCTTAGATCATCC 10pmol/µL 
Olig2
KlCreER
 AGCATTGCTGTCACTTGGT 10pmol/µL 
Olig2 CACCGCCGCCCAGTTTGTCC 10pmol/µL 
Table 2. Primer sequences and concentration for genotyping PCR. 0.5µL per sample were 
used.  
 
 
Figure 7. Resulting gel from PCR genotyping. Double bands designate a transgenic mouse (ex. 
Lane #4, + control lane #8).  
 
Olig2Cre-ER mice were crossed with a reporter mouse line 
 To establish a transgenic mouse line that would express GFP in recombinant mice, an 
Olig2Cre-ER mouse was mated with a reporter mouse. Transgenic mice contained the Olig2Cre-
ER locus as well as a homozygous double-fluorescent Cre reporter strain mT/mG (Jackson 
Laboratory, Stock No. 007576) that identified Cre recombination by the replacement of tdTomato 
with EGFP expression upon addition of tamoxifen (Figure 7).  
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Figure 8. Olig2Cre-ER Reporter Mouse Transgene Construct. The expression of Cre 
is identified by the replacement of tdTomato with EGFP expression with the addition of 
tamoxifen in transgenic mice.
[11]
  
 
Testing the Olig2Cre-ER transgenic system in endogenous tissues 
  To test the Olig2Cre-ER system in our mice, a pregnant Olig2Cre-ER transgenic female 
mouse was sacrificed and E16 embryos were obtained. One embryo was transgenic based on tail-
tip genotyping as described above. The brain and section of spinal cord were dissected from the 
embryo and fixed in formalin. Tissues were then placed in sucrose. The next day, the tissues were 
washed in PBS and put into cryomold molds in OCT in preparation for sectioning. The brain was 
cross-sectioned and the spinal cord was sectioned longitudinally.  
 
Fibroblast Extraction 
Next, fibroblasts were extracted from a transgenic mouse to establish a source of cells for 
multiple experiments. A pregnant Olig2Cre-ER female mouse was sacrificed at Day 15 and 10 
embryos were removed. Yolk sacs were used for genotyping. Each embryo was dissected, 
discarding the spinal cord and head region. Limbs were dissected and a scalpel was used to create 
smaller pieces of tissue. Fibroblasts were grown on gelatin-coated flasks from passage 0 to 
passage 5 and multiple vials were frozen down in 1mL cryovials once cells were confluent on a 
T175 flask. 
  
Cell Culture and Maintenance 
 Mouse embryonic fibroblasts, balbc fibroblasts, and plat-e cells were all maintained in 
MEF basal media with media changes and passaging when cells came to about 80% confluency. 
MEF basal media consists of 450 mL HiGlucose DMEM, 50mL FBS, 5mL L-Glutamine, and 
5mL Anti-Anti. With every passage, some cells were frozen down in media and freezing media 
which consists of 90% FBS and 10% DMSO.  
  14 
  
Plasmid Preparation 
 Before virus production, plasmids for each gene were prepared. The Origene Powerprep 
HP Plasmid Maxi kit with pre-filters protocol was used to prepare purified DNA plasmids for 
FoxG1, Brn2, Sox2, and GFP. Each plasmid was obtained by first pelleting cultures 100mL 
overnight. Cells were then suspended in 20mL suspension buffer containing RNase A. Following 
suspension, cells were lysed with 10mL cell lysis solution and incubated at room temperature for 
5 minutes. 10mL of neutralization buffer was added and mixed. After neutralization, the cell 
lysate was placed in an equilibrated prefilter/column. After flow stops, flow-through was 
discarded and the column was washed with 10mL wash buffer. The prefilter was then removed 
and the column was washed with 50mL wash buffer. The plasmid DNA was then eluted by 
adding 15mL of low salt elution buffer. DNA was precipitated by adding 10.5mL isopropanol. 
The solution was mixed and centrifuged at 15,000 x g at 4 degrees Celsius for 30 minutes. The 
pellet was washed with 5mL of 70% ethanol and centrifuged at the same speed for 5 more 
minutes. The ethanol wash was pipetted off and was air dried for 10 minutes. The resulting pellet 
was dissolved in 500µL TE buffer and stored at -20 degrees Celsius.  
 
Retrovirus Production: 
 For all retrovirus production, the Plat-E cell line, a retrovirus packaging line, was used. 
Plat-E cells contain an EF1α promoter and yield a stable retroviral structure protein expression of 
gag, pol, and ecotropic env 
[30]
. Plat-E cells were transfected with transfection reagents and DNA 
and retroviral supernatant was collected on various days for MEF infection.  
 
X-treme Gene Method 
 The first retrovirus production method attempted was the X-treme gene method from 
Roche Applied Sciences. Plat-E cells were thawed, passaged, and 2 million cells were plated on 
gelatin-coated 10cm dishes. 9µg of plasmid DNA was added to 27µL of X-treme Gene 
transfection reagent in 300µL serum-free DMEM. The solution was added drop wise to each 
10cm dish. P2 Olig2Cre-ER fibroblasts were plated onto 2 gelatin-coated T-25 flasks in MEF 
media. On day 1, the supernatant was collected and filtered. MEF media was replaced on each 
10cm dish. On day 2, the secondary virus was collected and filtered. 4mL of the primary 
collection was added to 4mL of the secondary collection and 8µL of 8µg/mL polybrene was 
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added. 4mL of virus was added to each T-25 flask with fibroblasts. On day 3, virus was replaced 
with 4mL of fresh virus supernatant. On day 4, media was changed on each T-25 flask. 
 
Calcium Phosphate Method 
 Due to low efficiency with the X-treme gene method, calcium phosphate was used in the 
next set of retrovirus production experiments. CaCl2 transfection method was used to produce a 
retrovirus using the plasmid DNA of FoxG1, Brn2, Sox2, and GFP. Plat-E cells were thawed and 
plated onto 2 gelatin-coated T-25 flasks. The following day, Plat-E’s were passaged to a T-175 
flask. On day 3, Plat-Es were passaged to 2 million cells per 10cm dish (gelatin-coated) in 8mL 
of MEF media. On day 4, 2x Hepes-Buffered Saline (HBS) was made and titrated to a pH of 6.95. 
5mL conical tubes were labeled for each plasmid and 1mL of DPEC water was added to each. 
112.5µL of 10x CaCl2 was added to the water and mixed by hand. 35µg of each DNA plasmid 
was added to the appropriate tube and mixed by hand. 1.125mL of 2x HBS was added drop wise 
from about 3 inches above the solution and was mixed by pipetting up and down 5 times. 
1.125mL of the final solution was added drop wise to each 10cm dish and placed in a 3% CO2 
incubator for 24 hours. On day 5 the media was removed from each 10cm dish and replaced with 
DMEM Hi-Glucose + 2% FBS. GFP transfection was observed under fluorescence to show 
transfection efficiency. Passage 2 Olig2Cre-ER fibroblasts were plated at 125,000 cells per well 
of a poly-ornithine coated 6-well plate. The first retrovirus collection occurred on day 6. 
Supernatant was collected from the 10cm dishes using a 60mL syringe and luerlock 0.22µm 
filter. Supernatant was replaced with fresh 2% FBS media. 24 hours later the supernatant was 
removed from each 10cm plate and 8µg/mL polybrene was added. Supernatant was added to the 
fibroblasts drop wise and incubated.  
 
PEI Method 
 A third method was attempted and resulted in the highest transfection efficiency. This 
retrovirus production method uses the PEI reagent. The PEI reagent may be ordered from 
Polysciences (cat # 23966-2). A stock solution is made by dissolving PEI in endotoxin-free dH2O, 
heated to around 80 C.  fter cooling to room temperature, the solution is neutrali ed to a p  of 
 .0, filtered using a 0.22 M filter, and stored at -20 C. Plat-E cells were thawed, plated on a T175 
flask and left for 3 days in MEF media. Cells were then passaged and 2 million cells were plated 
on to gelatin-coated 10cm dishes. The virus was made with DMEM with no serum, 9 µg of the 
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plasmid DNA and 27 µL of the PEI reagent. To assess virus efficiency, GFP plasmid was 
transfected into Plat-E cells, infected into MEFS and were assessed by immunofluorescence.  
 
FoxG1/Brn2 Reprogramming Protocol 
 A protocol taken from Lujan et al. that was published in 2012 was used with minor 
changes (Figure 8). The reprogramming protocol began 24 hours after transfection. Media was 
replaced with N3 medium which consisted of 100 mL DMEM F12, 25µg/mL insulin, 50µg/mL 
transferrin, 30nM sodium selenite, 20nM progesterone, 100nM peutriscine, 10ng/mL FGF2, and 
10ng/mL EGF. Cells were left for 24 days with media changes every three days. 100µM 
tamoxifen (1µL/mL) was administered to each well during the first media change and at each 
subsequent media change. On day 24, media was changed to OPC differentiation media 
consisting of 10ng/mL FGF2, 10ng/mL PDGF, and 10nM forskolin. After five days media was 
changed to OPC differentiation media consisting of 200nM absorbic acid and 30ng/mL T3 and 
left for five more days. It was previously published that PDGF and bFGF maintain 
oligodendrocyte progenitor cells that will not differentiate spontaneously into oligodendrocytes 
[26]
. After immunofluorescence analysis, cells were fixed and stained for Olig2 and Nkx2.2, Tuj1 
and GFAP, and Pax6 and Nestin. 
 
Figure 9. Protocol for reprogramming. After transfection with FoxG1 and Brn2, cells 
underwent a 34 day protocol with media changes every 3 days.  
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Direct Reprogramming with Sox2  
 Following the Ring et al protocol, MEFs were used for direct reprogramming using the 
single factor, Sox2 (Figure 9). MEFs were plated onto 10cm dishes for retroviral transfection. 
One day after transfection cells were passaged and plated onto 6-well plates coated with poly-
ornithine. Media was changed to NSC-BM+++ which consisted of DMEM F12, B27 Supplement, 
N2 Supplement, EGF, and bFGF. Cells were left for 10 days with media changes every other day. 
On day 11, cells were collected with accutase and plated onto uncoated low attachment 6-well 
plates. Cells were cultured for 5-7 days and spheres were collected and plated onto poly-ornithine 
coated plates. A total of three rounds of neurosphere and monolayer expansion were performed. 
After 31 total days with passages to monolayer cultures every 3-5 days, cells could be 
characterized.  
 
 
Figure 10. Protocol for reprogramming. Sox2 transfected MEFs and Balbcs underwent an 
approximate 30 day protocol with 3 rounds of neurosphere formation and monolayer expansion. 
 
 
Immunohistochemistry 
 To assess transgene expression in transfected fibroblasts, a sample of cells was used for 
antibody staining. Cells were fixed in 1mL 10% formalin for 15 minutes then washed for 2 
minutes in 2mL PBS. Cells were washed in PBS 2 more times for 5 minutes. Cells were then 
blocked in 0.5mL donkey serum and 9.5mL PBS-T for 30 minutes. Block was removed and 
1000µL of the diluted primary antibody was added to the well. Primary antibodies were ordered 
from Abcam and were diluted 1:1000 in block (Table 3). Cells were left in   C overnight. The 
next day, cells were washed 3 times with PBS-T. The secondary antibody, diluted 1:500, was 
  18 
added and left for 1 hour at room temperature. Cells were then washed with PBS-T and 1mL 
PBS-T was left on each well for microscopy verification.  
 
Antibody Animal Concentration Dilution Company/Catalog# 
FoxG1 Goat 0.5mg/mL 1:1000 Abcam: ab3394 
Brn2 Rabbit 0.5mg/mL 1:1000 Abcam: ab94977 
Sox2 Mouse  1:1000 R&D: MAB2018 
Table 3. Primary Antibodies used for immunohistochemistry. Secondary antibodies used 
were all Alexafluor 488 diluted 1:500.  
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Results 
 
Olig2 Cre-ER system shows GFP and Olig2 Expression in the brain and spinal cord 
  Spinal cord and brain slices showed Cre GFP+ expression of endogenous 
oligodendrocytes of E16 mice (Figure10). Brain also showed Olig2 antibody expression 
(Figure11). 
 
 
 
  
Figure 11. Spinal cord and brain sections showing GFP+ oligodendrocytes. E16 
transgenic mouse shows GFP expression after tamoxifen administration.  Images = 40x 
Scale bar = 50µM 
 
 
 
Figure 12. Brain section showing Olig2 expression near GFP+ oligodendrocytes. Olig2 
antibody expression (Alexafluor 647) is consistent with GFP+ oligodendrocytes in an E16 
transgenic mouse (arrows).  Scale bar = 50µM 
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PEI was the most effective retrovirus production protocol 
 After obtaining or making the DNA plasmids, three virus production methods were used 
to create viruses that efficiently transfected plat-e cells and mouse embryonic fibroblasts (MEFs). 
The X-Treme Gene protocol produced almost no transfection of plat-e cells based on 
immunofluorescence (data not shown). The calcium phosphate method produced GFP positive 
plat-e cells; however, the transfection efficiency of MEFs was only about 30% for each gene 
resulting in a double transfection efficiency of FoxG1 and Brn2 at about 15% (Figure 12). The 
third protocol attempted involved the use of the transfection reagent, polyethylenimine (PEI). The 
PEI method resulted in 90-100% GFP transfection of plat-e cells and MEFs in two different 
experiment attempts, proving to be the most efficient method for this protocol (Figure 12).  
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Figure 13. GFP Transfection using CaCl2 and PEI protocols. A.) CaCl2 protocol produces low 
GFP positive plat-E cells. B-E.) Two transfections using the PEI protocol. PEI produces a high 
number of GFP positive plat-e cells and high transfection in MEFs. Scale bar = 50 µm 
 
 
 
Mouse Embryonic Fibroblasts without viruses do not produce GFP+ cells or change morphology 
 Controls of mouse embryonic fibroblasts without virus transfection were used to assess 
the possibility of any GFP+ cells or change in morphology due to cytokines or components of the 
medium. MEFs were plated following the same protocol as the virus-transfected cells and were 
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maintained in the same medium over the 34 day protocol. Microscopy showed no GFP+ 
fluorescence at day 1 or day 21 and cells maintained the original red fluorescence (Figure 13). 
MEFs were also given tamoxifen to ensure the Olig2Cre-ER system would not produce GFP+ 
cells without FoxG1 and Brn2 transfection. There were not GFP+ cells after tamoxifen 
administration (Figure 14). 
 
 
 
Figure 14. MEFs without virus transfection are not Olig2+, maintain tdTomato 
fluorescence, and do not change morphology in N3 medium. Left A.) Day 1 phase picture 
shows normal MEF morphology. B.) MEFs maintain endogenous tdTomato fluorescence. C.) 
MEFs do not show any GFP+ cells. Right A-C.)  Day 21 MEFs phase, tdTomato, and GFP 
microscopy images. Scale bar = 100µm. 
  23 
 
 
Figure 15. MEFs without virus transfection with tamoxifen do not produce GFP+ Olig2 
cells. A.) Phase picture of MEFs.  B.)  tdTomato positive MEFs. C.)  No GFP+ cells. Scale Bar = 
100µM 
 
PEI protocol retroviruses efficiently transduce cells 
 After an appropriate retrovirus production protocol was established, the reprogramming 
protocol previously published was attempted to convert mouse embryonic fibroblasts to induced 
neural progenitor cells and then differentiated into oligodendrocyte progenitor cells. MEFs 
transfected with the FoxG1 and Brn2 retroviruses were plated onto poly-ornithine coated 6-well 
plates and maintained in N3 Medium. A sample of cells was plated onto gelatin-coated plates and 
primary antibodies were added for FoxG1 and Brn2. Secondary antibodies were added and 
assessed with immunofluorescent microscopy. Alexafluor 488+ FoxG1/Brn2 positive cells were 
counted as well as DAPI stained cells and transfection efficiency was determined comparing the 
number of positive cells versus total cells. Four fields of view were used for counting resulting in 
181/249 Brn2 cells and 91/124 FoxG1 cells. Both FoxG1 and Brn2 retroviral transfection resulted 
in about 73% positive cells (Figure 15).  
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Figure 16. FoxG1 (Left)  and Brn2 (Right) expression transfected MEFs. A &E.) tdTomato 
positive MEFs after transfection. B&F.) Alexafluor 488+ cells for FOXG1/Brn2. C&G.)  DAPI 
Staining. D&H.) Merge images. Scale = 100µM 
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FoxG1 and Brn2 transfected cells show changes in morphology 
 Previous studies reported that mouse embryonic fibroblasts after transfection showed 
morphological changes beginning at day 4 and significant morphological changes at day 7 where 
cells showed an elongated shape. Colony formation was first observed at day 13 
[25] 
(Figure 16).  
We saw similar morphological changes beginning at day 3 with colonies forming at day 14 
(Figure 17).  
 
Figure 17. Time-lapse images of FoxG1 + Sox2 infected cells 
[24]
. MEFs show morphological 
changes starting as early as day 4 with elongation at day 7. Colonies began forming at days 13-
16.  
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Figure 18. Morphological changes of transfected MEFs over 18 days. A.) Day 3 MEFs show 
normal fibroblast morphology with some elongated structures. B.)  Day 9 MEFs begin to form 
elongated cells and have areas of clumping. C-D.) MEFs form colonies. Scale bar = 100µm 
 
 
No GFP+ cells were identified over the 24 day protocol. After day 24, N3 medium was 
replaced with OPC differentiation medium as proposed in the established protocol 
[25]
.Cells were 
confluent the first day of OPC differentiation (day 24); however, cell colonies broke up and 
significant cell death occurred from day 24 to day 34 (Figure 18). There were no GFP+ cells 
determined by fluorescent microscopy (Figure 19). Cells were stained for multiple factors 
including Olig2, Nkx2.2, Tuj1, Nestin, Pax6, and GFAP. Cell staining was negative. 
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Figure 19. Morphological changes during OPC differentiation. A-B.) Phase contract images 
of transfected MEFs at Day 1 (Left) and Day 10 (Right) of OPC differentiation. C-D.) tdTomato 
positive MEFs. E-F.) There are no GFP+ cells during or after OPC differentiation. Images = 10x 
Scale bar = 100µm 
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Figure 20. Fluorescent microscopy of day 24 MEFs. A.)  MEFs are still positive for 
endogenous tdTomato. B.)  There are no GFP+ cells at the first day of OPC 
differentiation.  Scale = 100µm 
 
Sox2 transfected cells change morphology but are easily contaminated 
 Sox 2 transfected MEFs were done in parallel with the FoxG1/Brn2 protocol using a 
protocol previously published 
[40]
. Cells were transfected on day 0 and left with media changes 
until day 11 in which the first neurosphere stage began. Cell morphology changes dramatically 
over the first 11 days and neurospheres were formed after placement onto uncoated low 
attachment 6-well plates. However, at day 20 it was noticed that cells that were not yet given 
tamoxifen fluoresced green (Figure 20). The GFP+ cells were replated for the monolayer stage 
and assessed on day 22. Although cells could still form a monolayer and undergo expansion, they 
fluoresced green and had lost the endogenous red fluorescence (Figure 21). We believe this is due 
to contamination of neural stem cells in the NSC basal medium that was used. The contaminant 
cells took over the expansion and all Olig2Cre-ER fibroblasts died. Other experiments performed 
resulted in green cells as well. Further experimentation done with new media resulted in 
expanding cells that endogenously fluoresced red and no green; however, this experiment could 
not be completed and images were only obtained for day 2 and day 11 (Figure 22).  
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Figure 21. Sox2 transfected MEFs change morphology and fluoresce green without 
tamoxifen. A.) Sox2 MEFs on day 1. B.) Sox2 MEFs on day 8, form colonies. C.) Sox2 
Neurospheres on day 18. D.) Sox2 MEFs exhibit green fluorescence on day 20 despite no 
addition of tamoxifen. Scale = 100 µm 
 
 
 
 
 
Figure 22. Sox2 MEFs replated for monolayer expansion. A.) Sox2 MEFs during monolayer 
expansion on day 22. B.) Sox2 MEFs exhibit green fluorescence without tamoxifen. C.) Sox2 
MEFs on day 22 show no endogenous red fluorescence. Scale = 100 µm 
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Figure 23. Sox2 MEFs have morphological changes with no contamination. A-B.) Sox2 
MEFs phase images on day 2(Left) and day 11(Right). C-D.) Endogenous tdTomato fluorescence 
expression of Sox2 MEFs. E-F.) Sox2 MEFs do not express GFP. Scale bar = 100µm 
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 A total of 9 experimental runs were attempted, each with varying virus type and 
transfection methods (Table 4). As shown in the table, some experiments were not carried to 
completion for the full 30-34 day protocol duration. Others were completed with no GFP+ cells at 
the end of the 24 days or after OPC differentiation. Transfection efficiencies did increase as the 
PEI transfection method was practiced using retrovirus transfection.  
 
Experiment 
Number 
Virus Type Transfection 
Method 
Transfection 
Efficiency 
Results 
1 Lentivirus X-Treme Gene N/A No GFP+ with 
doxycycline 
2 Retrovirus X-Treme Gene N/A No GFP + with 
tamoxifen (D24) 
3 Retrovirus CaCl2 N/A Contaminated 
4 Retrovirus X-Treme Gene <10% No GFP+ (D34) 
5 Retrovirus CaCl2 ~34% No GFP+ 
6 Retrovirus PEI <15% No GFP+ (D22) 
7 Retrovirus PEI ~80% Lost after D11 
8 Retrovirus PEI ~73% Lost after D11 
9 Retrovirus PEI N/A Death after 
tamoxifen 
Table 4. Description of all experimental runs. Throughout experiments the virus type and 
transfection methods were altered to obtain high efficiency.  
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DISCUSSION 
Direct reprogramming has become a new strategy for development of a specific cell type that 
may be useful for cell transplantation. Past studies have demonstrated the reprogramming 
potential of a variety of cell types including skeletal muscle, cardiomyocytes, pancreatic beta 
cells and neural cells 
[13]
. Further research has shown that progenitor cells are the most useful cell 
type for transplantation because they can differentiate into a specific-cell type, lessening the 
chances of unwanted cell types taking over the injured or diseased area. Taking into consideration 
past studies from Wernig’s group as well as others, we hypothesi ed that direct reprogramming is 
a useful technique to generate oligodendrocyte progenitor cells with a future potential of being 
used for spinal cord injury therapies.  
 The protocols used were previously published and resulted in two different cell stages. 
FoxG1 and Brn2 cells resulting from the protocol were described as bipotent neural precursor 
cells 
[24]
 while cells from the Sox2 protocol resulted in neural progenitor cells, both of which we 
hoped to expand with differentiation into OPCs 
[38]
. Studies occurring after these two protocols 
show a variation in the stages of OPC formation and the reprogramming factors chosen 
[54][46][31]
. 
We chose to use the least number of reprogramming factors necessary in hopes to obtain a more 
simple protocol; however, many limiting factors still existed. For example, three retrovirus 
production methods were tried before efficient reprogramming numbers were obtained. This may 
be due to the individual methods, or in the case with FoxG1 and Brn2, it may be due to each virus 
being made separately and then transfected into the cells. This limits the chances that each cell 
will receive both genes. It took subsequent experiments to obtain a high enough efficiency that 
would allow for the possibility of reprogramming. In the original paper as well as others, a 
lentivirus with transcriptional control using a TetO promoter was used, which varies from our 
protocol. Wernig’s publication in 2013 states that induced OPC generation is still at a low 
efficiency and therefore increasing the viral titer of the reprogramming factors is necessary. The 
group also recommends that further experimentation to understand the appropriate stoichiometry 
and expression levels of the factors are needed 
[54]
.  
 Other technical issues decreased chances of effective reprogramming including cell 
proliferation. Specifically for the Sox2 transfection, balbc fibroblasts often died upon viral 
transfection. The mouse embryonic fibroblasts originally harvested and frozen away were 
difficult to thaw and grow efficiently. These technical issues limited the number of viable cells 
for viral transfection that could survive and differentiate. FoxG1/Brn2 transfected cells in one 
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trial were proliferating and had morphological changes until the OPC differentiation media was 
added. After day 24 there was prolific cell death, suggesting that something in the differentiation 
media was not appropriate to maintain cells. Another technical issue is the addition of tamoxifen 
at appropriate concentrations. Late experiments using newly-made tamoxifen in the same 
concentration resulted in cell death around day 12, suggesting the ratio was not correct. These 
technical issues greatly limited the potential of a successful experiment. 
 Future experimentation should take into consideration any technical difficulties such as 
cell viability, tamoxifen ratio, media components, etc. Therefore, any difficulties due to these 
issues may be resolved before reprogramming experiments are attempted. It would be beneficial 
to try to produce a double construct vector for the FoxG1 and Brn2 genes so that each transfected 
cell would receive both genes, ultimately increasing the transfection efficiency; or utilize a 
lentiviral system previously published by other groups. Another alternative is to try a variety of 
transcription factors other than FoxG1 and Brn2. Although it is easier using one or two 
transcription factors, it may be more efficient using another combination. Many groups have 
published reprogramming reports of neural stem cells and OPCs using a variety of combinations 
suggesting that it is possible to use more than two factors.  
 Finally, the ultimate purpose of these experiments was to generate autologous OPCs that 
would myelinate axons in vivo. If further experimentation produces reprogrammed cells it will be 
necessary to test the cells in a mouse or rat model of demyelination such as a shiverer mouse or 
rat with a spinal cord injury. For any future clinical application, the cells must migrate and 
myelinate in vivo for an extended period of time. Once the mouse system is well understood, 
direct reprogramming of OPCs will need to be extended with the use of human somatic cells as 
the starting cell population. Other areas of experimentation will need to include culturing 
techniques that are serum-free and are done in consideration with good manufacturing practice 
guidelines so that the cells are appropriate for transplant into humans. Although other techniques 
exist that produce OPCs, direct reprogramming holds the potential of producing a faster method 
for obtaining OPCs for not only autologous transplants to improve function after SCI but also 
patient-specific models of disease and models for drug screening or understanding of OPC 
development.  
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